Resource impact statement
No significant resource impact is anticipated
NICE has recommended naldemedine, within its marketing authorisation, as an option for treating opioid-induced constipation in adults who have had laxative treatment.
We do not expect this guidance to have a significant impact on resources; that is, the resource impact of implementing the recommendations in England will be less than £5 million per year in England (or £9,000 per 100,000 population).
This is because naldemedine is a further treatment option and the overall cost of treatment will be similar to the current treatment options available.
This technology is generally commissioned by clinical commissioning groups. NHS England commissions services for patients with constipation only when referral to a specialist centre is required. Services for opioid-induced constipation are provided in both primary and secondary care.
This page was last updated: 30 September 2020